Sutro Biopharma, Inc.
NASDAQ:STROBiotechnology
+$0.32 today
- Market cap
- $141.11M
- Beta
- 1.55
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$1,174.12
Volume 0.31M
Average 0.28M
STRO Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Sutro Biopharma, Inc.NASDAQ: STRO
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares declines year over year
Q1 FY2026 weighted avg shares of 130.82K shares fell 98.4% year over year, behind the -22.0% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 98.5% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -98.4% toward the trailing-twelve-month pace of -22.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 8.5M USD
- Year-over-year change
- +10.6%
- 4-year CAGR
- +16.5%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.5M | +10.6% |
| FY2024 | 2024-12-31 | 7.68M | +27.7% |
| FY2023 | 2023-12-31 | 6.02M | +18.6% |
| FY2022 | 2022-12-31 | 5.07M | +10.0% |
| FY2021 | 2021-12-31 | 4.61M | — |
Weighted Avg Shares vs competitors
How STRO compares with its peers on the latest reported figures
- STRO's LTM Mar 2026 weighted avg shares of 6.42M shares is the lowest of the 9 companies compared; the peer median is 58.58M shares.
- Its year-over-year change of -22.0% is the lowest of 9, against a peer median of +25.9%.
- Over three fiscal years its annual growth of +18.8% compares with a peer median of +15.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 84.8M | +66.7% | +18.0% | |
| LTM Mar 2026 | 68.77M | +14.6% | +15.0% | |
| LTM Mar 2026 | 66.33M | +37.1% | +16.8% | |
| LTM Mar 2026 | 61.49M | +1.3% | +13.5% | |
| FY2025 | 55.66M | +0.8% | +0.4% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | 24.5M | +1.8% | +11.6% |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | 21.01M | +341.4% | +66.1% |
| LTM Mar 2026 | 12.13M | +61.6% | +63.6% | |
| LTM Mar 2026 | 6.42M | -22.0% | +18.8% | |
| Peer median (excluding STRO) | 58.58M | +25.9% | +15.9% | |
Competitors are the stored peer set for STRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 61.88M | 67.77M | 153.73M | 62.04M | 102.48M |
| Cost of Revenue | 9.77M | 8.29M | 6.82M | 7.22M | 7.32M |
| Gross Profit | 52.11M | 59.48M | 146.92M | 54.83M | 95.16M |
| Gross Margin | 84.2% | 87.8% | 95.6% | 88.4% | 92.9% |
| Research & Development | 104.4M | 137.17M | 180.43M | 252.04M | 166.42M |
| Selling, General & Admin | 56M | 59.54M | 62.58M | 48.45M | 41.02M |
| Operating Expenses | 150.63M | 188.43M | 236.19M | 293.28M | 200.11M |
| Depreciation & Amortization | 4.84M | 8.29M | 6.82M | 7.22M | 7.32M |
| EBITDA | (97.56M) | (105.07M) | (67.92M) | (180.45M) | (145.65M) |
| EBITDA Margin | -157.7% | -155.0% | -44.2% | -290.9% | -142.1% |
| Operating Income | (98.52M) | (128.94M) | (89.28M) | (238.45M) | (104.95M) |
| Operating Margin | -159.2% | -190.3% | -58.1% | -384.3% | -102.4% |
| Interest Income | 577K | 3.46M | 14.51M | 44.43M | 9.25M |
| Interest Expense | 3.14M | 3.35M | 23.75M | 31.07M | 38.21M |
| Other Income / Expenses | (7.01M) | 12.24M | 677K | 13.36M | (86.23M) |
| Income Before Tax | (105.54M) | (116.7M) | (88.6M) | (225.1M) | (191.18M) |
| Pre-Tax Margin | -170.6% | -172.2% | -57.6% | -362.8% | -186.5% |
| Income Tax Expense | 0 | 2.5M | 18.19M | 2.36M | (93K) |
| Net Income | (105.54M) | (119.2M) | (106.79M) | (227.46M) | (191.09M) |
| Net Margin | -170.6% | -175.9% | -69.5% | -366.6% | -186.5% |
| EPS (Basic) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| EPS (Diluted) | (22.90) | (23.50) | (17.80) | (29.60) | (22.49) |
| Weighted Avg Shares | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
| Weighted Avg Shares (Diluted) | 4.61M | 5.07M | 6.02M | 7.68M | 8.5M |
Sutro Biopharma, Inc.
NASDAQ:STRO
Intrinsic Alpha fair value
Locked
Current Price
$8.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.